Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can targeted drugs boost surgery success in Hard-to-Treat lung cancer?

NCT ID NCT07829744

NEW Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are testing whether giving targeted therapy before and after surgery helps people with stage III non-small cell lung cancer that has specific rare gene changes. The study includes 190 adults whose tumors have alterations in genes like EGFR, ALK, ROS1, MET, RET, or KRAS. Treatment is chosen based on the tumor's genetic profile, and the main goal is to see how much cancer remains in the tumor after the pre-surgery treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
targeted therapy drugs matched to specific tumor gene changes
What this could lead to
If it works, this approach could give people with stage III lung cancer and rare gene changes a better chance of successful surgery and longer remission.
What could go wrong
This is a phase 2 trial, so it is too early to know if the strategy helps in the long run. Targeted therapies can cause side effects, and not all tumors respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 190 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * Histologically or cytologically confirmed stage III NSCLC (AJCC 8th edition), considered resectable or potentially resectable. * Documented EGFR exon 20 insertion, ALK fusion, ROS1 fusion, MET exon 14 skipping alteration, RET fusion, or KRAS G12C mutation. * At least one measurable lesion per RECIST 1.1 and ECOG performance status 0-1. * Adequate cardiopulmonary and major organ function for surgery. * Written informed consent and willingness to comply with study procedures, sample collection, and follow-up. Exclusion Criteria: * Stage III NSCLC considered unresectable by surgical assessment. * Lung cancer treatment within the previous 2 years, or prior lung cancer with a remission duration of less than 2 years. * Another malignancy within the previous 5 years. * Major surgery within 28 days before the first study dose. * Any contraindication to the assigned targeted therapy. * Inability or unwillingness to provide informed consent or comply with study requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer (NSCLC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.